{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:10:22Z","timestamp":1790165422822,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106841","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:40:15Z","timestamp":1784043615000},"page":"106841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fc\u03b3 receptor (Fc\u03b3R) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3926-7127","authenticated-orcid":false,"given":"Thomas","family":"Kartika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Buitrago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cunningham-Rundles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9078-7155","authenticated-orcid":false,"given":"Barry S.","family":"Coller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106841_bib1","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1182\/bloodadvances.2024014009","article-title":"Btk inhibition: the importance of being selective","volume":"8","author":"Flaumenhaft","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106841_bib2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cancers13051103","article-title":"Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease","volume":"13","author":"von Hundelshausen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rpth.2026.106841_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106841_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/17512433.2022.2106968","article-title":"Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Jiang","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.rpth.2026.106841_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2019.100018","article-title":"X-linked agammaglobulinemia (XLA): phenotype, diagnosis, and therapeutic challenges around the world","volume":"12","author":"El-Sayed","year":"2019","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.rpth.2026.106841_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.0105-2896.2005.00325.x","article-title":"Role of ITAM-containing adapter proteins and their receptors in the immune system and bone","volume":"208","author":"Humphrey","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.rpth.2026.106841_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.766272","article-title":"Bruton\u2019s tyrosine kinase inhibitors impair FcgammaRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia","volume":"12","author":"Naylor-Adamson","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.rpth.2026.106841_bib8","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/bloodadvances.2019000617","article-title":"Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcgammaRIIA): a new option in HIT?","volume":"3","author":"Goldmann","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106841_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.749022","article-title":"Effects of the Btk-inhibitors remibrutinib (LOU064) and rilzabrutinib (PRN1008) with varying Btk selectivity over Tec on platelet aggregation and in vitro bleeding time","volume":"8","author":"Duan","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.rpth.2026.106841_bib10","doi-asserted-by":"crossref","first-page":"11526","DOI":"10.1073\/pnas.94.21.11526","article-title":"Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors","volume":"94","author":"Wahl","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2026.106841_bib11","article-title":"Conformational switches that control the TEC kinase\u2014PLCgamma signaling axis","volume":"6","author":"Lowe","year":"2022","journal-title":"J Struct Biol X"},{"key":"10.1016\/j.rpth.2026.106841_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2023000503","article-title":"Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond","volume":"2023","author":"Greinacher","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2026.106841_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100283","article-title":"Heparin-induced thrombocytopenia: an illustrated review","volume":"7","author":"May","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106841_bib14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3324\/haematol.2021.280366","article-title":"Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy","volume":"107","author":"Greinacher","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106841_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMc2413301","article-title":"Maternal anti-PF4 antibodies as cause of neonatal stroke","volume":"392","author":"Hausler","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106841_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031855","article-title":"Critical analysis of thrombocytopenia associated with glycoprotein IIb\/IIIa inhibitors and potential role of zalunfiban, a novel small molecule glycoprotein inhibitor, in understanding the mechanism(s)","volume":"12","author":"Rikken","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.rpth.2026.106841_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1172\/JCI36745","article-title":"Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain","volume":"119","author":"Gao","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rpth.2026.106841_bib18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rpth.2026.106841_bib19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2026.106841_bib20","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-16-0939","article-title":"Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in cynomolgus monkeys\u2014mechanism and monitoring","volume":"23","author":"Guffroy","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rpth.2026.106841_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-9560-5-7","article-title":"Increased platelet expression of FcGammaRIIa and its potential impact on platelet reactivity in patients with end stage renal disease","volume":"5","author":"Serrano","year":"2007","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2026.106841_bib22","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jacc.2024.08.051","article-title":"Platelet FcgammaRIIa as a marker of cardiovascular risk after myocardial infarction","volume":"84","author":"Schneider","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2026.106841_bib23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00018-009-0207-z","article-title":"Platelet-bacterial interactions","volume":"67","author":"Kerrigan","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.rpth.2026.106841_bib24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/jth.12905","article-title":"Human platelet IgG Fc receptor FcgammaRIIA in immunity and thrombosis","volume":"13","author":"Arman","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106841_bib25","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/bloodadvances.2024015076","article-title":"Platelet-activating histone\/antihistone IgG complexes in anti-PF4-negative thrombosis and thrombocytopenia syndrome","volume":"9","author":"Esefeld","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106841_bib26","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1055\/a-1481-3039","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors","volume":"121","author":"von Hundelshausen","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106841_bib27","first-page":"2203","article-title":"VITT after ChAdOx1 nCoV-19 vaccination","volume":"385","author":"Weber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106841_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/09537104.2020.1849600","article-title":"Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases","volume":"32","author":"Harbi","year":"2021","journal-title":"Platelets"},{"key":"10.1016\/j.rpth.2026.106841_bib29","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI79070","article-title":"Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets","volume":"125","author":"Hitchcock","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rpth.2026.106841_bib30","article-title":"Association of C-type lectin-like receptor 2 and galectin-1 with portal vein system thrombosis in HBV-related liver cirrhosis","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.rpth.2026.106841_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1538-7836.2011.04614.x","article-title":"Podoplanin-expressing inflammatory macrophages activate murine platelets via CLEC-2","volume":"10","author":"Kerrigan","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106841_bib32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106841_bib33","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.3324\/haematol.2018.207183","article-title":"Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions","volume":"104","author":"Series","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106841_bib34","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/bloodadvances.2019000640","article-title":"Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin alphaIIbbeta3 in mice and humans","volume":"3","author":"Dobie","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106841_bib35","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","article-title":"Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib","volume":"1","author":"Bye","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106841_bib36","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106841_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.rpth.2026.106841_bib38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/16078454.2020.1730080","article-title":"Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction","volume":"25","author":"Ninomoto","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.rpth.2026.106841_bib39","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/ATVBAHA.115.306130","article-title":"Ibrutinib inhibits platelet integrin alphaIIbbeta3 outside-in signaling and thrombus stability but not adhesion to collagen","volume":"35","author":"Bye","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2026.106841_bib40","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.3324\/haematol.2017.179044","article-title":"Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients","volume":"103","author":"Alberelli","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106841_bib41","doi-asserted-by":"crossref","first-page":"C902","DOI":"10.1152\/ajpcell.00296.2020","article-title":"Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function","volume":"320","author":"Zheng","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.rpth.2026.106841_bib42","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/ijms23010076","article-title":"Spontaneous platelet aggregation in blood is mediated by Fc\u03b3RIIA stimulation of Bruton\u2019s tyrosine kinase","volume":"23","author":"Duan","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rpth.2026.106841_bib43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2019.218545","article-title":"Low-dose Btk inhibitors selectively block platelet activation by CLEC-2","volume":"106","author":"Nicolson","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106841_bib44","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3324\/haematol.2018.193391","article-title":"Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI","volume":"103","author":"Nicolson","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106841_bib45","first-page":"1663","article-title":"Rapid tyrosine phosphorylation and activation of Bruton\u2019s tyrosine\/Tec kinases in platelets induced by collagen binding or CD32 cross-linking","volume":"95","author":"Oda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106841_bib46","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A role for Bruton\u2019s tyrosine kinase (Btk) in platelet activation by collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr Biol"},{"key":"10.1016\/j.rpth.2026.106841_bib47","doi-asserted-by":"crossref","first-page":"24680","DOI":"10.1074\/jbc.M413411200","article-title":"Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation","volume":"280","author":"Nanda","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2026.106841_bib48","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1161\/ATVBAHA.108.168971","article-title":"A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability","volume":"28","author":"Herrera-Galeano","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2026.106841_bib49","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-02-202614","article-title":"A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways","volume":"114","author":"Jones","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106841_bib50","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/ng.604","article-title":"Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists","volume":"42","author":"Johnson","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.rpth.2026.106841_bib51","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2010-11-320788","article-title":"Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression","volume":"118","author":"Faraday","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106841_bib52","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2011-11-392787","article-title":"A novel mechanism of sustained platelet \u03b1IIb\u03b23 activation via PEAR1","volume":"119","author":"Kauskot","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106841_bib53","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCGENETICS.111.964627","article-title":"Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes","volume":"6","author":"Lewis","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.rpth.2026.106841_bib54","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12863-015-0217-9","article-title":"Genome-wide association study of platelet aggregation in African Americans","volume":"16","author":"Qayyum","year":"2015","journal-title":"BMC Genet"},{"key":"10.1016\/j.rpth.2026.106841_bib55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ajhg.2016.05.005","article-title":"Platelet-related variants identified by exomechip meta-analysis in 157,293 individuals","volume":"99","author":"Eicher","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.rpth.2026.106841_bib56","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2217\/pgs-2021-0022","article-title":"Genetic variants of PEAR1 and ischemic clinical outcomes in coronary artery disease patients: a systematic review and meta-analysis","volume":"22","author":"Zhang","year":"2021","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.rpth.2026.106841_bib57","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fphar.2018.00490","article-title":"Variants of PEAR1 are associated with outcome in patients with ACS and stable CAD undergoing PCI","volume":"9","author":"Stimpfle","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.rpth.2026.106841_bib58","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106841_bib59","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/hae.12503","article-title":"Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project","volume":"20","author":"Elbatarny","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106841_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.rpth.2026.106841_bib61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V74.1.182.182","article-title":"Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa\/IIa and an indirect interaction with platelet GPIIb\/IIIa mediated by adhesive proteins","volume":"74","author":"Coller","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106841_bib62","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1172\/JCI110973","article-title":"A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and\/or IIIa","volume":"72","author":"Coller","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rpth.2026.106841_bib63","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/bloodadvances.2018024950","article-title":"Synthetic glycopolymers and natural fucoidans cause human platelet aggregation via PEAR1 and GPIbalpha","volume":"3","author":"Kardeby","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106841_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100433","article-title":"BTK-inhibitor drug covalent binding to lysine in human serum albumin using LC-MS\/MS","volume":"42","author":"Muste","year":"2022","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.rpth.2026.106841_bib65","article-title":"Bruton\u2019s tyrosine kinase\u2014a new target for immune mediated inflammatory diseases?","volume":"72S","author":"Isaacs","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rpth.2026.106841_bib66","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1056\/NEJMc2309016","article-title":"Rescue therapy in chronic prothrombotic autoimmune anti-PF4 disorder","volume":"389","author":"Lindhoff-Last","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106841_bib67","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMc1309710","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Rushworth","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106841_bib68","first-page":"1569","article-title":"The anti-leukemic Bruton\u2019s tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism","volume":"44","author":"Uckun","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.rpth.2026.106841_bib69","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2017-09-808808","article-title":"Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans","volume":"131","author":"Busygina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106841_bib70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.imlet.2012.12.007","article-title":"Bruton\u2019s tyrosine kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints","volume":"150","author":"Hsu","year":"2013","journal-title":"Immunol Lett"},{"key":"10.1016\/j.rpth.2026.106841_bib71","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3960\/jslrt.25028","article-title":"BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL","volume":"65","author":"Kojima","year":"2025","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.rpth.2026.106841_bib72","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/leu.2016.316","article-title":"Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib","volume":"31","author":"Kazianka","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.rpth.2026.106841_bib73","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-0039-1677744","article-title":"Optimizing platelet GPVI inhibition versus haemostatic impairment by the Btk inhibitors ibrutinib, acalabrutinib, ONO\/GS-4059, BGB-3111 and evobrutinib","volume":"119","author":"Denzinger","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106841_bib74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.vph.2018.08.007","article-title":"Intracellular platelet signalling as a target for drug development","volume":"111","author":"Vilahur","year":"2018","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.rpth.2026.106841_bib75","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.1974.tb06675.x","article-title":"Willebrand factor and ristocetin. I. Mechanism of rustocetin-induced platelet aggregation","volume":"28","author":"Jenkins","year":"1974","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106841_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093569","article-title":"Echicetin coated polystyrene beads: a novel tool to investigate GPIb-specific platelet activation and aggregation","volume":"9","author":"Navdaev","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2026.106841_bib77","first-page":"318","article-title":"Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor","volume":"85","author":"Allain","year":"1975","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.rpth.2026.106841_bib78","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1309\/AJCPP43SEYCBJLHJ","article-title":"Reference range determination for whole-blood platelet aggregation using the multiplate analyzer","volume":"142","author":"Peerschke","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.rpth.2026.106841_bib79","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V91.2.491","article-title":"Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb\/IIIa, and von Willebrand factor do not","volume":"91","author":"Kehrel","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106841_bib80","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","article-title":"Tec regulates platelet activation by GPVI in the absence of Btk","volume":"102","author":"Atkinson","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106841_bib81","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-5793(97)00926-5","article-title":"Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain","volume":"413","author":"Gibbins","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.rpth.2026.106841_bib83","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/09537104.2019.1610166","article-title":"Platelet glycoprotein VI genetic quantitative and qualitative defects","volume":"30","author":"Jandrot-Perrus","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.rpth.2026.106841_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100592","article-title":"Clinical significance of altered collagen-receptor functioning in platelets with emphasis on glycoprotein VI","volume":"38","author":"Nurden","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2026.106841_bib85","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MOH.0000000000000805","article-title":"A role of platelet C-type lectin-like receptor-2 and its ligand podoplanin in vascular biology","volume":"31","author":"Suzuki-Inoue","year":"2024","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.rpth.2026.106841_bib92","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1182\/bloodadvances.2024012713","article-title":"Selective Btk inhibition by PRN1008\/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice","volume":"8","author":"Smith","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106841_bib93","doi-asserted-by":"crossref","first-page":"11557","DOI":"10.1074\/jbc.M114.629527","article-title":"Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets","volume":"290","author":"Manne","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2026.106841_bib86","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0049-3848(97)00037-6","article-title":"Anticoagulant fucoidan fractions from Fucus vesiculosus induce platelet activation in vitro","volume":"85","author":"D\u00fcrig","year":"1997","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106841_bib87","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1074\/jbc.M112.424473","article-title":"Fucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2)","volume":"288","author":"Manne","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2026.106841_bib88","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41467-023-36486-0","article-title":"SVEP1 is an endogenous ligand for the orphan receptor PEAR1","volume":"14","author":"Elenbaas","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.rpth.2026.106841_bib89","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177357","article-title":"LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis","volume":"134","author":"Shen","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rpth.2026.106841_bib90","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jtha.2022.10.008","article-title":"Heparin and heparin proteoglycan-mimetics activate platelets via PEAR1 and PI3K\u03b2","volume":"21","author":"Kardeby","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106841_bib91","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/bjh.70029","article-title":"Differential modulation of Bruton's tyrosine kinase inhibitor selectivity on platelet GPVI and integrin \u03b1IIb\u03b23 bidirectional signalling via BTK\/PLC\u03b32\/PKC\u03b8 affects haemostasis and thrombosis","volume":"207","author":"Zhang","year":"2025","journal-title":"Br J Haematol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926034990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926034990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:58:53Z","timestamp":1790164733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926034990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926034990"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106841","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fc\u03b3 receptor (Fc\u03b3R) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106841"}}